Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The treatment period was 16 weeks, the initial dose, 5 mg, was unforcedly titrated to 10 mg,
20 mg and 40 mg after confirming tolerance at weeks 4, 8 and 12. The primary endpoint for
efficacy was the change in the urinary protein/creatinine ratio from baseline to the end of
treatment. The secondary endpoint was creatinine clearance (Ccr).